Inhibitors targeting N-glycosylation modification of PD-L1 have been consistently reported to inhibit tumor progression and improve the efficacy of immunotherapy23,24, as supported by our data showing that NGI-1-NPs improved the efficacy of aPD-1 or aPD-L1 by increasing T cell infiltration in tumors. The gene discussed is CD274; the disease is neoplasm.